BioSpace News Archive

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today provided key program and business updates.

Chemence Medical, Inc., a manufacturer and distributor of adhesive-based medical devices, announced it received Food and Drug Administration clearance to market and sell the Exofin® Precision Pen as a new medical device for wound closure.

SiSaf Ltd, a company developing RNA therapeutics for rare genetic skeletal disorders, today announced that it has appointed Professor Michael J. Econs, MD as Clinical Advisor.

Orphazyme A/S Company today announces that Chief Executive Officer (CEO) Christophe Bourdon will resign from his position as CEO at Orphazyme.

Immune-Onc Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for IO-202, a first-in-class antibody targeting leukocyte immunoglobulin-like receptor B4 (LILRB4, also known as ILT3), for the treatment of solid tumors.

As stated in the January 20, 2022 release, once the clinical data has been tabulated, the final results will be filed with the U.S. Food & Drug Administration for Emergency Use Authorization (EUA) consideration.

Trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity.

Fusion oncogenes, such as RET- and NTRK- gene fusions, are associated with more invasive pediatric thyroid cancers, correlating with the highest risk of metastases.

Abbott enables distribution of twice the number of STEM kits to support STEM learning for all fifth grade students in Des Plaines Community Consolidated School District 62.

OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE), today announced acceptance of the IND obtained by Veloxis Pharmaceuticals, Inc. from the Food & Drug Administration (FDA) for a clinical trial with VEL-101/FR104.